The safety of medication use has long been the primary concern of patients with haemophilia A. In the time when plasma-derived FVIII was the only choice, the high risk of disease transmissions, such as AIDS and hepatitis B, made patients reluctant to take infusion therapy regularly and influenced their adherence. Here, F8 is linked to hemophilia A.